Our system has noticed that you are based in United States, but the current country setting is Uganda. Do you still want to change your country?

Expert Insights

Your Needs Are Driving Our Innovation!

In close collaboration with universities and research institutions, WACKER’s corporate R&D team of over 200 researchers continuously develops new production platforms and technologies for all types of biopharmaceuticals including recombinant proteins, live microbial products, pDNA, mRNA and LNPs. The R&D scientific team has secured patents for more than 200 different patents and applications across these diverse areas. They are also involved with 35+ active academic and industry collaborations.

Stapel Magazine auf einem Tisch

To show you additional content, we need your permission to set cookies. Please accept “Functional Cookies” in your cookie settings.

Engage the Experts at Wacker Biotech

A few of our scientific leaders talk about the challenges and rewards of the exciting new field of mRNA therapeutics. In June 2024, we opened our state-of-the-art competence center in Halle, Germany to ramp up mRNA capacity and meet the growing demand for expert mRNA process development and manufacturing.

To show you additional content, we need your permission to set cookies. Please accept “Functional Cookies” in your cookie settings.

A Dedication to R&D, Manufacturing and Client Success

mRNA is a completely new modality with no established textbook or manufacturing process. Dr. Sebastian Schuck shares how a strong focus on R&D in WACKER’s Munich headquarters combined with the personalized approach Wacker Biotech can offer as mid-sized CDMO have given the firm early mover advantage in the field of mRNA vaccines and therapeutics

To show you additional content, we need your permission to set cookies. Please accept “Functional Cookies” in your cookie settings.

The Innovation Pipeline

Dr. Christian Hundshammer discusses how innovation is driving the advanced therapeutics field, from AI-based genetic sequence optimizations and mRNA formulations to targeted delivery for cell and gene therapies.

Wacker Biotech is a science-driven CDMO proud to work on the cutting edge of new innovations for human health.

To show you additional content, we need your permission to set cookies. Please accept “Functional Cookies” in your cookie settings.

The mRNA IP Landscape

Advanced therapeutics typically require a highly personalized approach tailored to a particular patient cohort. WACKER brings together the right facilities, scales and teams of experts to deliver these customized approaches.

And our platforms such as a proprietary strain for producing plasmid DNA make it easier to navigate a complex IP landscape.

To show you additional content, we need your permission to set cookies. Please accept “Functional Cookies” in your cookie settings.

Bridging R&D and GMP

mRNA is inherently an unstable molecule that requires robust process controls and analytics, especially when scaling up production.

Wacker Biotech scientists have many years of mRNA experience and are continually innovating alternative delivery platforms and new analytical methods for in-process checks.

Frau mit Kopfhörern von hinten

Better with WACKER

We look forward to bringing your biologics to life.

Contact us
Back to Wacker Biotech Home
Related:
Biopharma (Wacker Biotech) ESETEC® FOLDTEC® LIBATEC® Scientific Corner Why WACKER